Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease

Abstract

Patients with unresectable locally advanced NSCLC who are not candidates for concurrent chemoradiation have been excluded from trials with immunotherapy. Trials with cemiplimab are exception.

Trials EMPOWER-Lung 1 (first-line cemiplimab monotherapy) and EMPOWER-Lung 3 (first-line cemiplimab with chemotherapy) were not only focused on metastatic stage but also included patients mentioned above.

Keywords

• NSCLC (Non-Small-Cell Lung Cancer)
• locally advanced stage
• EMPOWER-Lung 1
• EMPOWER-Lung 3
• immunotherapy, cemiplimab